Allergan Plc (AGN)

166.02
0.08 0.05
NYSE : Health Technology
Prev Close 166.10
Open 166.31
Day Low/High 165.43 / 166.37
52 Wk Low/High 114.27 / 197.00
Volume 1.64M
Avg Volume 4.89M
Exchange NYSE
Shares Outstanding 328.03M
Market Cap 54.32B
EPS -15.30
P/E Ratio N/A
Div & Yield 2.96 (1.77%)
The Earnings Super Bowl: Cramer's 'Mad Money' Recap (Friday 1/25/19)

The Earnings Super Bowl: Cramer's 'Mad Money' Recap (Friday 1/25/19)

Jim Cramer's plan for getting through the heart of earnings season next week.

Jim Cramer: What Are We to Make of Today's Market Decline?

Jim Cramer: What Are We to Make of Today's Market Decline?

Is it a retest based on the damage the Fed has already done, the result of a breakdown in trade talks or a sign of a slowing global economy?

Power of Positives: Cramer's 'Mad Money' Recap (Thursday 1/17/19)

Power of Positives: Cramer's 'Mad Money' Recap (Thursday 1/17/19)

Jim Cramer talks about how this market is taking its cues from the positives, and shrugging off the negatives.

Jim Cramer: This Market Takes Its Cue From the Positive and Ignores the Negative

Jim Cramer: This Market Takes Its Cue From the Positive and Ignores the Negative

So far 2019 is proving to be a year where things have a habit of working out right.

Try This Allergan Two-Week Setup

Try This Allergan Two-Week Setup

The company is set to report earnings on Jan. 29, so traders have a couple of weeks to watch the action.

Tumultuous, but Positive: Cramer's 'Mad Money' Recap (Friday 1/11/19)

Tumultuous, but Positive: Cramer's 'Mad Money' Recap (Friday 1/11/19)

This will be the craziest reporting season we've seen in ages, says Jim Cramer. He's got your game plan for next week.

Allergan Must Prove Itself With Signs of More Aggressive Buying

Allergan Must Prove Itself With Signs of More Aggressive Buying

A three-year decline in the shares of the maker of Botox will take more than a two-week bounce to reverse.

FAANG Is Back: Cramer's 'Mad Money' Recap (Tuesday 1/8/19)

FAANG Is Back: Cramer's 'Mad Money' Recap (Tuesday 1/8/19)

Plus: Jim Cramer interviews Apple CEO Tim Cook about innovation, investments and healthcare technology.

Real Money Post Industrial Average Outperformed the Market in 2018

Real Money Post Industrial Average Outperformed the Market in 2018

The RMPIA index was up for the year, while the S&P 500, DJIA, Russell 2000 and Nasdaq all finished 2018 in the red.

The Charts of Allergan Look Very Bearish With New Lows Made Yesterday

The Charts of Allergan Look Very Bearish With New Lows Made Yesterday

When I looked at the charts this morning I found a stock that could still decline further.

Fighting the Fed: Cramer's 'Mad Money' Recap (Wednesday 12/19/18)

Fighting the Fed: Cramer's 'Mad Money' Recap (Wednesday 12/19/18)

Buying stocks now means you are in the uncomfortable position of fighting the Fed as it tries to slow the economy.

Jim Cramer: My Take on These Companies Where Lawsuits Are Front and Center

Jim Cramer: My Take on These Companies Where Lawsuits Are Front and Center

These are currently situations where companies are facing serious lawsuits.

Allergan Pulls Breast Implant Off European Markets Due to Cancer Risk

Allergan Pulls Breast Implant Off European Markets Due to Cancer Risk

Allergan's textured breast implants have been linked to a rare form of cancer.

Who Are the 9 Highest-Paid CEOs and How Much Do They Make?

Who Are the 9 Highest-Paid CEOs and How Much Do They Make?

The CEOs who bring in the most money every year may not be who you expect. Who are the highest-paid CEOs?

Aegon Is Driving Financial Performance Through Simplification And Growth

Aegon Is Driving Financial Performance Through Simplification And Growth

At today's Analyst and Investor Conference hosted in New York, CEO Alex Wynaendts and Aegon's US management team will outline how targeted actions to simplify and grow the business are creating significant value for all stakeholders.

I Anticipated Some Volatility Today but I Didn't Expect a Total Collapse

Still, there were some bullish aspects to the action today much as you might think otherwise.

Upcoming Portfolio Review

We'll be out later with key thoughts from our discussion on what direction the portfolio should be taken as we quickly approach a new investment year.

Aegon UK Extends Partnership With Atos For Administration Services

Aegon UK Extends Partnership With Atos For Administration Services

Aegon today announces that its subsidiary in the United Kingdom has strengthened its existing partnership with Atos, signing a 15-year contract to service and administer its Existing Business (non-platform customers).

Aegon Will Propose To Reappoint Alex Wynaendts As CEO

Aegon Will Propose To Reappoint Alex Wynaendts As CEO

Aegon's Supervisory Board will propose to the Annual General Meeting of Shareholders in May 2019 to reappoint Alex Wynaendts (58) as Chief Executive Officer of the company, for a four-year term.

Allergan Needs to Rebase on the Charts - Don't Rush It

Allergan Needs to Rebase on the Charts - Don't Rush It

Let's check the charts and technical indicators for some guidance.

A One-Two Punch to the Bears: Cramer's 'Mad Money' Recap (Thursday 11/1/18)

A One-Two Punch to the Bears: Cramer's 'Mad Money' Recap (Thursday 11/1/18)

Jim Cramer's been saying that that if the Fed or the president blink in their wars against inflation and China you could have an up day. That's what we got.

Jim Cramer: Even Safe-Haven Big-Cap Drug Stocks Are Now Broken

Jim Cramer: Even Safe-Haven Big-Cap Drug Stocks Are Now Broken

Once the safest stocks in the book, the big-cap drug companies are now toxic.

Allergan Shares Fall Despite Q3 Beat, Increased Guidance

Allergan Shares Fall Despite Q3 Beat, Increased Guidance

The Dublin firm raised its outlook amid a delay in the launch of generic competition to its dry eye medication Restasis.

US Stocks Rebound as Earnings Drive Sentiment Amid Renewed Trade War Concerns

US Stocks Rebound as Earnings Drive Sentiment Amid Renewed Trade War Concerns

Global stocks attempted yet another rebound Tuesday, with reports of direction market intervention in China supporting prices in Asia and stronger-than-expected blue chip earnings putting European bourses on solid footing following a volatile session on Wall Street that saw a 900-point swing for the Dow Jones Industrial Average and a further worrying plunge in big-name tech companies.

Staying Long Apple Into Tuesday's Product Launch: Market Recon

Staying Long Apple Into Tuesday's Product Launch: Market Recon

My target price and panic points have changed, and I am watching for a chance to add or shave some off, depending on which direction the stock takes.

Procter & Gamble, Western Digital, Allergan: 'Mad Money' Lightning Round

Procter & Gamble, Western Digital, Allergan: 'Mad Money' Lightning Round

Jim Cramer weighs in on Procter & Gamble, Six Flags, Western Digital, Allergan, Principal Financial Group.

Risk and Uncertainty: Cramer's 'Mad Money' Recap (Monday 7/30/18)

Risk and Uncertainty: Cramer's 'Mad Money' Recap (Monday 7/30/18)

Jim Cramer says somebody panicked, and their departure left behind a mess in the tech sector. But that spells a buying opportunity.

Aegon: Transamerica Settles Universal Life Litigation

Aegon: Transamerica Settles Universal Life Litigation

Aegon's subsidiary Transamerica today announces an agreement that would resolve litigation challenging certain monthly deduction rate adjustments on universal life insurance policies in the United States.

Jim Cramer: These Are the Stocks to Buy on Canada Deal and the 4th Quarter

Jim Cramer: These Are the Stocks to Buy on Canada Deal and the 4th Quarter

Straying from these names could land you in quicksand as the 4th quarter begins.

TheStreet Quant Rating: C (Hold)